BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer Pharmaceutical Investing
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 Life Science Investing
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT Pharmaceutical Investing
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Life Science Investing
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development Pharmaceutical Investing
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa Life Science Investing
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma Life Science Investing
